Earnings Miss: Irving, TX-based Exxon Mobil Corporation (XOM - Free Report) reported earnings per share at 92 cents, below the Zacks Consensus Estimate of $1.26. Following the underperformance, the stock fell more than 3% in the pre-market trading.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate for the quarter has been revised upward over the last seven days.
However, ExxonMobil’s earnings surprise history is not impressive. The company failed to beat the Zacks Consensus Estimate in three of the last four quarters, the average negative earnings surprise being 5.7%.
Revenue: Revenues of $73,501 million were higher than the Zacks Consensus Estimate of $70,252 million.
Key Stats: Production averaged 3.647 million barrels of oil-equivalent per day (MMBOE/d), lower than 3.922 MMBOE/d in the year-ago quarter. Liquid production fell year over year to 2.212 million barrels per day (MMB/D) from 2.269 MMB/D. Also, natural gas production was 8.613 MMCF/d (millions of cubic feet per day), down from 9.920 MMCF/d in the year-ago period.
Zacks Rank: Currently, ExxonMobil has a Zacks Rank #3 (Hold) but that could change following its second-quarter 2018 report which has just released. You can see the complete list of today’s Zacks #1 Rank stocks here.
Check back later for our full write up on this ExxonMobil’s earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Earnings Miss: Irving, TX-based Exxon Mobil Corporation (XOM - Free Report) reported earnings per share at 92 cents, below the Zacks Consensus Estimate of $1.26. Following the underperformance, the stock fell more than 3% in the pre-market trading.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate for the quarter has been revised upward over the last seven days.
However, ExxonMobil’s earnings surprise history is not impressive. The company failed to beat the Zacks Consensus Estimate in three of the last four quarters, the average negative earnings surprise being 5.7%.
Revenue: Revenues of $73,501 million were higher than the Zacks Consensus Estimate of $70,252 million.
Key Stats: Production averaged 3.647 million barrels of oil-equivalent per day (MMBOE/d), lower than 3.922 MMBOE/d in the year-ago quarter. Liquid production fell year over year to 2.212 million barrels per day (MMB/D) from 2.269 MMB/D. Also, natural gas production was 8.613 MMCF/d (millions of cubic feet per day), down from 9.920 MMCF/d in the year-ago period.
Zacks Rank: Currently, ExxonMobil has a Zacks Rank #3 (Hold) but that could change following its second-quarter 2018 report which has just released. You can see the complete list of today’s Zacks #1 Rank stocks here.
Check back later for our full write up on this ExxonMobil’s earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on XOM - FREE